Actuate Therapeutics, Inc. Common stock (ACTU) Stock Analysis
Actuate is a clinically promising but financially fragile oncology bet, where elraglusib’s pancreatic cancer survival data offers major upside if the company can survive its near-term cash cliff.
Overview
Actuate Therapeutics is a pre-revenue clinical-stage oncology company centered on elraglusib, a first-in-class GSK-3β inhibitor designed to suppress cancer survival pathways, reduce resistance, and enhance immune activity. Its strongest evidence is in metastatic pancreatic cancer, where elraglusib plus chemotherapy improved median overall survival and doubled one-year survival rates. The opportunity spans pancreatic cancer, melanoma, pediatric cancers, and RAS-driven tumors, with IV and oral formulations in development. However, the company remains loss-making, highly capital constrained, and dependent on regulatory progress, partnerships, and dilutive financing.